Glofitamab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 199 publications
The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 07, 2026
α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026
Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: July 06, 2026
Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.
Journal: Leukemia & lymphoma
Published: July 06, 2026
The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.
Journal: Cancers
Published: July 01, 2026
Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.
Journal: Oncology (Williston Park, N.Y.)
Published: June 22, 2026
A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.
Journal: Pathophysiology : the official journal of the International Society for Pathophysiology
Published: June 12, 2026
Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: June 10, 2026
Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas.
Journal: Expert opinion on drug discovery
Published: June 08, 2026
Sequential glofitamab and consolidative ASCT plus CAR-T therapy achieved durable remission in relapsed/refractory DLBCL.
Journal: Blood science (Baltimore, Md.)
Published: May 26, 2026
Last Updated: 09/26/2026